Results 151 to 160 of about 45,236 (268)

Novel optimization of multi‐mechanistic approaches for the acute treatment of a migraine attack: A review

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1181-1192, May 2026.
Abstract Objective To highlight key factors required to optimize multi‐mechanistic approaches with oral combination treatments for the acute management of a migraine attack. Background Given the complex multi‐factorial nature of migraine, combining treatments with different mechanisms of action should improve outcomes compared to monotherapies, but ...
Stephen Silberstein, Alan M. Rapoport
wiley   +1 more source

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1128-1147, May 2026.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

CGRP-empowered stem cell sheet/short nanofiber sponge <i>via</i> enhancing neurovascular coupling for bone regeneration. [PDF]

open access: yesMater Today Bio
Jia Y   +10 more
europepmc   +1 more source

Delayed urticaria during treatment with anti‐CGRP monoclonal antibodies in migraine

open access: yesHeadache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1193-1199, May 2026.
Abstract Objective To characterize clinical presentation and management of urticaria associated with calcitonin gene‐related peptide (CGRP) ‐targeting monoclonal antibodies (mAbs) for migraine prophylaxis. Background CGRP‐targeting mAbs are effective in migraine prophylaxis, but have been associated with hypersensitivity reactions, including urticaria.
Christoph T. Berger   +5 more
wiley   +1 more source

Animal Models of Hunner‐Type Interstitial Cystitis

open access: yesInternational Journal of Urology, Volume 33, Issue 5, May 2026.
ABSTRACT Background Animal models are crucial for mechanistic studies and therapeutic development of human diseases. At present, the etiology of interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic disease of the urinary bladder, remains undefined.
Yoshiyuki Akiyama, Yi Luo
wiley   +1 more source

Emerging mechanisms of ILC2‐neuronal crosstalk across the body

open access: yesImmunology &Cell Biology, Volume 104, Issue 5, Page 439-442, May‐June 2026.
Emerging roles of ILC2 in neuronal crosstalk across organs. In a series of studies published in 2025, ILC2 were shown to regulate nervous system function across a range of organs across the body. Within the intestinal tract, ILC2‐derived cytokines acted on enteric neurons to orchestrate immunity to helminths (Wang et al).
David A Posner, Matthew R Hepworth
wiley   +1 more source

Home - About - Disclaimer - Privacy